Delcath (DCTH) Moves Higher as FDA Grants Chemosaturation System NDA Standard Review
Tweet
Share
E-mailGet Alerts DCTH Hot Sheet
Join SI Premium – FREE
Shares of Delcath Systems, Inc. (Nasdaq: DCTH) are ripping higher in early trading Monday following an announcement that its chemosaturation system with melphalan hydrochloride for injection NDA was accepted by the FDA for standard review.
In the release, the implied PDUFA date should be no later than June 15, 2013.
Delcath is up about 7 percent of so in early trading. For more from the release, click here.
In the release, the implied PDUFA date should be no later than June 15, 2013.
Delcath is up about 7 percent of so in early trading. For more from the release, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Creative Medical completes enrollment in ADAPT back pain trial
- FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
